Supernus Pharmaceuticals, Inc.
$51.25
▼
-1.87%
2026-04-21 09:40:00
www.supernus.com
NGM: SUPN
Explore Supernus Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.92 B
Current Price
$51.25
52W High / Low
$59.68 / $29.16
Stock P/E
—
Book Value
$18.48
Dividend Yield
—
ROCE
-3.31%
ROE
-3.68%
Face Value
—
EPS
$-0.68
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
778
Beta
0.73
Debt / Equity
3.86
Current Ratio
1.91
Quick Ratio
1.66
Forward P/E
12.01
Price / Sales
4.06
Enterprise Value
$2.65 B
EV / EBITDA
59.7
EV / Revenue
3.69
Rating
Strong Buy
Target Price
$63.17
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | SCYNEXIS, Inc. | $1.07 | — | $47.85 M | — | -30.16% | -16.48% | $1.31 / $0.56 | $1.13 |
| 2. | PRF Technologies Ltd. | $2.64 | — | $2.31 M | — | -53.59% | -90.37% | $17.95 / $1.8 | $10.29 |
| 3. | Zoetis Inc. | $118.25 | 19.63 | $49.71 B | 1.64% | 27.18% | 65.99% | $172.23 / $113.29 | $7.84 |
| 4. | ANI Pharmaceuticals, Inc. | $81.73 | 23.13 | $1.81 B | 0.06% | 6.99% | 16.16% | $99.5 / $56.71 | $25.8 |
| 5. | Aquestive Therapeutics, Inc. | $4.24 | — | $527.23 M | — | -62.98% | 178.61% | $7.55 / $2.12 | $-0.28 |
| 6. | SIGA Technologies, Inc. | $4.57 | 14.06 | $327.41 M | 0% | 11.76% | 11.23% | $9.62 / $4.29 | $2.78 |
| 7. | China SXT Pharmaceuticals, Inc. | $2.06 | — | $1.97 M | — | -17.13% | -50.3% | $1,046.98 / $1.25 | $26.16 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 211.57 M | 192.1 M | 165.45 M | 149.82 M | 174.16 M | — |
| Operating Profit | 13.82 M | -60.23 M | 12.14 M | -2.6 M | 21.76 M | — |
| Net Profit | -4.11 M | -45.12 M | 22.5 M | -11.83 M | 15.33 M | — |
| EPS in Rs | -0.07 | -0.78 | 0.39 | -0.21 | 0.27 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 718.95 M | 661.82 M | 607.52 M | 667.24 M |
| Operating Profit | -36.86 M | 75.56 M | 13.4 M | 45.61 M |
| Net Profit | -38.55 M | 73.86 M | 1.32 M | 60.71 M |
| EPS in Rs | -0.67 | 1.28 | 0.02 | 1.05 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.45 B | 1.37 B | 1.28 B | 1.7 B |
| Total Liabilities | 390.93 M | 332.34 M | 356.16 M | 816.3 M |
| Equity | 1.06 B | 1.04 B | 921.52 M | 886.2 M |
| Current Assets | 644.18 M | 686.07 M | 493.11 M | 734.15 M |
| Current Liabilities | 338.17 M | 292.4 M | 290.2 M | 687.96 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 47.33 M | 171.95 M | 111.08 M | 116.83 M |
| Investing CF | 4.11 M | -189.87 M | 268.73 M | -216.66 M |
| Financing CF | 9.13 M | 12.19 M | -397.88 M | -10.48 M |
| Free CF | 45.99 M | 171.23 M | 110.53 M | 116.41 M |
| Capex | -1.34 M | -0.72 M | -0.55 M | -0.41 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 8.94% | -8.95% | — | — |
| Earnings Growth % | 5512.84% | -97.83% | — | — |
| Profit Margin % | 11.16% | 0.22% | 9.1% | — |
| Operating Margin % | 11.42% | 2.21% | 6.84% | — |
| Gross Margin % | 88.23% | 86.21% | 86.93% | — |
| EBITDA Margin % | 26.94% | 14.82% | 22.98% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.